Skip to main content

Bioo Scientific Receives $500K NSF Grant to Develop RNAi-Delivery Tech

Premium

Bioo Scientific this week announced that it has received a two-year, $500,000 grant from the National Science Foundation to develop a targeted, in vivo RNAi-delivery technology.

The award, a phase II Small Business Innovation Research grant, will specifically fund Bioo Scientific's work on its so-called Targeted Transport Technology, which the company said involves linking an "RNAi-agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules.

"The RNAi agent-loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by" the antibody, Bioo Scientific added. "The RNAi agent is then released to reduce the expression of its intended target."

The company expects to use the technology to create RNAi-delivery products for use in animal research.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.